Novo Nordisk's launch of weight-loss and diabetes drugs Wegovy and Ozempic in India hinges on resolving supply issues. The company is scaling up production and may consider local fill-finish options. Currently, the injectable forms are not approved in India, leading to high demand in grey markets.
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.